Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06617208 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pilot IntraOperative Neuronal Electrophysiology in Tumor rElatEd suRgery

Study acronym: PIONEER
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 7 months later Jun 1, 2029 → Jan 1, 2030
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Erasmus Medical Center

Record History

  1. Notable Primary and study completion pushed from Jun 1, 2029 to Jan 1, 2030 Primary endpoint(s) modified · Recruitment opened · Enrollment increased: 10 → 20 participants · 7 more Show 10 more changesShow less
    • Primary endpoint(s) modified
    • Recruitment opened
    • Enrollment increased: 10 → 20 participants
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 1, 2025 to Jan 1, 2026
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoint revised
    • Study description expanded, about 118 words
    • Publications: details revised at 7 of 7 entries
    • Study title revised
  2. Notable Start date: Jun 1, 2025 to Dec 1, 2025 Primary and study completion dates: Jan 1, 2029 to Jun 1, 2029v3 Show 1 more changeShow less
    • Primary and study completion dates: Jan 1, 2029 to Jun 1, 2029
  3. Notable Start date: Jan 1, 2025 to Jun 1, 2025v2
  4. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
670 trials monitored
See 44 trials at risk
668 trials monitored
See 40 trials at risk
INTRODUCTION AND RATIONALE Aggressive brain tumors like glioma have the ability to infiltrate the surrounding healthy brain tissue, disrupting normal neuronal activities and leading to impaired motor and cognitive functions, as well as causing epilepsy. This malignant brain tumor is considered one of the most challenging cancers to treat, with a median survival of 12 to 15 months. Recent findings on direct neuron-tumor interactions indicate that abnormal brain activity in the regions surrounding brain tumours may contribute to develop epilepsy and accelerating tumor growth. Tumors tend to 'fuel' themselves with neurotransmitters released during its 'daily' neuronal firing. Hyperactive neurons in the peritumoral cortex can form excitatory electrochemical synapses with surrounding tumor cells, creating direct communication pathways within the peritumoral microenvironment, which aids in the progression and proliferation of tumor cells via direct and paracrine signalling pathways. However, the specific features of this abnormal brain activity in the peritumoral cortex have not been fully clarified and information on the pathological changes of neuronal activity in glioma patients is largely lacking. To advance more effective treatment strategies, it is crucial to better understand the complex interactions between the tumor and the brain. This is especially important for our group of patients of which many perceive diminished quality of life because of epilepsy, cognitive functioning and language problems after tumor surgery. Furthermore, we lack thorough understanding of what tumor resection does to the original hyperactive peritumoral cortex and if resecting this is beneficial for improving postoperative outcome both for epilepsy as well as regarding survival. Therefore, identifying the hyperactive peritumoral cortex and directly addressing its impacts on the brain function and long-term surgical outcome could be a promising novel therapeutic strategy for treating glioma patients. STUDY AIM Our measurement focuses on capturing neuronal activity at single-neuron resolution in the peritumoral cortex of glioma patients using cortical depth electrodes. It is well-established that gliomas can remodel the surrounding brain tissue, leading to abnormal neuronal hyperactivity, which contributes to tumor progression and epilepsy. However, the specific neuronal patterns and underlying mechanisms of these changes are not yet fully understood. Our study will aim to collect detailed single-neuron recordings in this context, enabling us to map the precise neurophysiological disruptions caused by gliomas. On the long term, our research could lay the groundwork in identifying novel therapeutic approaches by providing critical in-sights into how gliomas alter brain function.
Trial Details
NCT Number NCT06617208
Lead Sponsor Erasmus Medical Center
Conditions Glioma, Glioblastoma (GBM), Brain Tumor-Glioma, Brain Metastasis
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov